Norbert Bischofberger, Gilead Sciences

2013 pay package: $5.6 million
2012 pay package: $5.4 million
Change: +4%
2013 compensation: $884,175 in salary; $1.7 million in stock awards; $1.8 million in option awards; $1 million in non-equity incentive plan compensation; $95,378 in other compensation

Norbert Bischofberger, who oversees R&D and serves as chief scientific officer at Gilead Sciences ($GILD), saw his take-home tick upward thanks a swelling bonus and a rise in stock awards. And, thanks to the work of Bischofberger and his sofosbuvir team, the value of those shares is likely only to rise.

After writing an $11 billion check for Pharmasset and mounting a fleet of combo and monotherapy studies, Gilead picked up FDA approval for its revolutionary hepatitis C drug in the fall, shortly breaking records for commercial launches and, now, awaiting a regulatory nod for a sofosbuvir-led cocktail therapy that promises to change the standard of care.

While that drug, marketed as Sovaldi, gets most of the attention, Gilead has put together an impressive pipeline of late-stage therapies, led by the targeted cancer drug idelalisib. The treatment, picked up in Gilead's $600 million deal for Calistoga, is a PI3K-delta blocker that fights non-Hodgkin's lymphoma, and it's currently up for FDA review. If approved, the breakthrough-designated therapy would compete against Johnson & Johnson ($JNJ) and Pharmacyclics' ($PCYC) Imbruvica and Roche's ($RHHBY) Gazyva in the blood cancer space, and Thomson Reuters figures idelalisib's peak sales will come in around $500 million a year.

All that sits atop Gilead's pioneering work in HIV and AIDS treatment, much of which is also a credit to Bischofberger. The Austrian scientist joined Gilead in 1990 and later led the team that developed Tamiflu, eventually rising to executive vice president and playing a role in the development programs that became Viread and Truvada.

- here's Gilead's compensation table

For more:
Special Reports: An ominous trend resurfaces as new drug approvals plunge in 2013 - Sovaldi: Gilead hits pay dirt with a breakthrough hep C drug | Which Big Biotechs are hitting the gas pedal on R&D spending?
Editor's Corner: The 5 biggest trends in biopharma R&D in 2013
Gilead scores early PhIII success for idelalisib in chronic lymphocytic leukemia

Norbert Bischofberger, Gilead Sciences

Suggested Articles

The data, from two patients with severe blood disorders, are "promising” for what could be a one-and-done treatment, Cantor Fitzgerald analysts wrote.

The fund will back pharma companies as well as developers of medtech products and providers of outsourced services.

The money will fund work to develop polymers in multiple indications and an associated U.S. expansion.